Astellas pays $3bn in cash for Audentes

14:40 EST 3 Dec 2019 | Elsevier Business Intelligence

Astellas Pharma Inc. is paying $60 per share (a 112% premium) in cash to acquire seven-year-old gene therapy firm Audentes Th...

Original Article: Astellas pays $3bn in cash for Audentes


More From BioPortfolio on "Astellas pays $3bn in cash for Audentes"

Quick Search

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...